IL10 and psoriasis vulgaris: The combined therapy could decrease the PASI score (mean difference = −1.45, 95% CI (-2.09, -0.80)) and inhibit inflammation (IL-10: mean difference = 1.16, 95% CI (0.94, 1.38); IL-17: mean difference = −2.06, 95% CI (-2.60, -1.51)) in psoriasis vulgaris patients.